MEK inhibitor-induced paronychia in a paediatric population: A tertiary centre experience

Ana Gusmão Palmeiro; Leandro Silva; Bernardo Pimentel; João Passos; Cecília Moura; Cristina Amaro

doi:10.1111/ajd.14079

MEK inhibitor-induced paronychia in a paediatric population: A tertiary centre experience

Australas J Dermatol. 2023 Aug;64(3):e245-e251. doi: 10.1111/ajd.14079. Epub 2023 May 24.

Authors

Ana Gusmão Palmeiro¹, Leandro Silva¹, Bernardo Pimentel¹, João Passos^{2

3}, Cecília Moura⁴, Cristina Amaro¹

Affiliations

¹ Dermatology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.
² Neurology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
³ Pediatric Neuro-Oncology Unit, Pediatrics Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
⁴ Dermatology Department, Instituto Português de Oncologia Francisco Gentil, Lisbon, Portugal.

PMID: 37224380
DOI: 10.1111/ajd.14079

Abstract

The cutaneous toxicity of MEK inhibitors may limit treatment adherence. The authors present a retrospective study of 41 paediatric patients with NF-1 undergoing therapy with selumetinib and propose a treatment algorithm.

Keywords: dermatology; drug adverse effects; neurofibromatosis; paronychia.

MeSH terms

Child
Humans
Mitogen-Activated Protein Kinase Kinases / adverse effects
Paronychia* / chemically induced
Protein Kinase Inhibitors / adverse effects
Retrospective Studies
Skin Diseases* / chemically induced

Substances

Protein Kinase Inhibitors
Mitogen-Activated Protein Kinase Kinases